A Phase 3 interventional study of Extended-release bupropion hydrochloride in Seasonal Affective Disorder, sponsored by GlaxoSmithKline. Completed at 51 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-23.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Seasonal Affective Disorder with a site in United States — none open to participants now, none under way, none of them phase 3. Seasonal Affective Disorder · United States.
Among the 18 studies in Seasonal Affective Disorder with a site in United States, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2002, is one of 2 in phase 3, and was the 4th registered.
31 studies on the registry are indexed under Seasonal Affective Disorder; 2 are open to participants now.
Browse Seasonal Affective Disorder studies →None of the 18 studies in Seasonal Affective Disorder with a site in United States is open now. The open studies under Seasonal Affective Disorder, anywhere →
Of the 1 Seasonal Affective Disorder study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 3 · Phase 4 1
First in 1995; this study’s year is marked. 4 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 60 across 25 interventional studies indexed under Seasonal Affective Disorder.
Median enrollment 61 across the 15 interventional studies, 73 across the 2 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 18 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 3 studies filed under Seasonal Affective Disorder — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Seasonal Affective Disorder with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a placebo controlled study evaluating the effectiveness of medication in preventing depressive episodes in subjects with a history of Seasonal Affective Disorder (SAD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Time between randomization and onset of a seasonal depressive episode. Proportion of depression-free subjects.
Change in HAMD-24 and -17 total score. Change in pain score.
Ran from Sep 2002 to primary completion in Jun 2003, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bupropion